Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

NCT06029595 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

517

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision by Sponsor; not due to safety reasons

Conditions

Uncontrolled Asthma

Interventions

DRUG: Experimental: CHF6001 3200 μg
DRUG: Placebo Comparator: CHF6001 Placebo

Sponsor

Chiesi Farmaceutici S.p.A.